Genetics Outlook 2019: CRISPR Technology Advances

With 2018 coming to a close, here's a look at the biggest genetics trends of the year and what's in...

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.

Cynata Therapeutics Completes Patent Application to Cover Cymerus Stem Cell Technology

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) announced that it has completed the filing of a...

Hemostemix Announces US FDA Clinical Trial Approval

Hemostemix (TSXV:HEM), a clinical-stage, autologous cell-therapy company, is pleased to announce that the United States Food and Drug Administration has raised...

ImmunoCellular Therapeutics Achieves Key Genetic Milestone in Research

This proof-of-concept trial proves what the company is able to do with its Stem-to-T-Cell program, but will it generate returns?

Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic Spinal Cord Injury

Neuralstem (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology,...

5 Top NASDAQ Biotech Stocks: Cardiome on Top

Cardiome, Avid, XBiotech, Fennec and Compugen were last week's five top-gaining NASDAQ biotech stocks. See what moved their share prices.